China's Growing Importance in Global Cancer Medicines

Area of Science:

• Health Policy
• Pharmaceutical Innovation
• Cancer Care Systems

Background:

• Global shift towards innovation-driven cancer care.
• China's rapid transformation of cancer medicine R&D, regulation, and financing over the past decade.
• Unique market-government coordination in China's healthcare system.

Purpose of the Study:

• Provide a comprehensive understanding of China's cancer medicine system transformations.
• Analyze the interplay of regulatory reforms, market access, and affordability strategies.
• Evaluate the impact of China's policies on innovation and accessibility.

Main Methods:

• Integrative framework combining historical development, regulatory reforms, market access, and affordability.
• Tracing the evolution of cancer medicine R&D from imitation to innovation.
• Examining interactions among regulatory oversight, pricing, and health insurance.

Main Results:

• China's drug regulatory reform (2015) accelerated R&D and international harmonization.
• Pricing and procurement policies expanded patient access and controlled costs.
• Multilayered financing improved affordability and sustainability for high-cost cancer medicines.

Conclusions:

• China's reforms have enhanced both innovation and accessibility in cancer care.
• Challenges remain in balancing innovation incentives with equitable access and fiscal sustainability.
• The Chinese experience offers valuable insights for global health policy reforms.